Assessing The Benefit Of Low Dose Aspirin In The Prevention Of Severe Sepsis.
Funder
National Health and Medical Research Council
Funding Amount
$391,880.00
Summary
Recent discoveries suggest that low doses of aspirin may save lives in patients with infection by limiting its severity. We will conduct a large-scale primary prevention study using daily low-dose aspirin to explore whether this widely used drug can safely prevent severe infection. This study is made possible by collaborative involvement in an existing Australian and USA funded study called ASPREE. Finding a treatment that helps prevent severe effects and outcomes of infection would be a major h ....Recent discoveries suggest that low doses of aspirin may save lives in patients with infection by limiting its severity. We will conduct a large-scale primary prevention study using daily low-dose aspirin to explore whether this widely used drug can safely prevent severe infection. This study is made possible by collaborative involvement in an existing Australian and USA funded study called ASPREE. Finding a treatment that helps prevent severe effects and outcomes of infection would be a major health advance.Read moreRead less
About 14,000 cases of bowel cancer occur annually in Australia despite the availability of life-saving screening. Most people do not receive recommended screening colonoscopy. We will look at why people at high-risk avoid screening and why people at average risk seek unnecessary screening. We will analyse family history and contacts with the healthcare system that impact screening decisions. We will determine the impact of screening on reducing the number of new cases and deaths.
The D-Health Trial: A Large-scale Population-based Trial Of Vitamin D Supplementation For Improving The Health Of Older Adults
Funder
National Health and Medical Research Council
Funding Amount
$2,591,860.00
Summary
The D-Health Trial is a randomised placebo-controlled trial of vitamin D supplementation for improving the health of older Australian adults. Over 21,000 people were recruited and randomised to monthly doses of vitamin D or placebo. This grant will enable completion of the planned 5 years of supplementation and long-term follow-up of mortality and cancer. The results of the trial will inform decisions about food fortification and/or supplementation with vitamin D.
A Longitudinal Investigation Of The Efficacy Of Pharmacological Smoking Cessation Aids In Real-life Settings
Funder
National Health and Medical Research Council
Funding Amount
$592,837.00
Summary
Currently around 3 million Australians, or 17% of people aged 14 years and over, smoke tobacco daily. These smokers are at major risk of developing coronary heart disease, stroke, peripheral vascular disease, and a variety of cancers, including lung, laryngeal, oral, kidney, bladder, breast, pancreas and colon cancers. At any one time almost half of Australian smokers intend to quit smoking or have already set a date to do so but few (around 10%) succeed on each attempt. Clinical trials of quitt ....Currently around 3 million Australians, or 17% of people aged 14 years and over, smoke tobacco daily. These smokers are at major risk of developing coronary heart disease, stroke, peripheral vascular disease, and a variety of cancers, including lung, laryngeal, oral, kidney, bladder, breast, pancreas and colon cancers. At any one time almost half of Australian smokers intend to quit smoking or have already set a date to do so but few (around 10%) succeed on each attempt. Clinical trials of quitting aids, such as nicotine patches, gum and Zyban, suggest that smokers are around twice as likely to quit if using these. However clinical trials are conducted in artificial environments and these quitting aids appear to have a far smaller impact on successful quitting rates in the 'real world'. Pharmaceutical quitting aids are heavily advertised by drug companies and widely used in Australia. Futhermore the Commonwealth Government has invested over $133 million dollars subsidising such aids to Australian smokers in the past four years. However it is not known to what extent these quitting aids have made a difference to Australian smoking rates. Sales volumes of pharmaceutical quitting aids appear not to have translated into expected increases in numbers of smokers successfully quitting, suggesting they are less effective than clinical trials suggest. The present study aims to investigate whether pharmaceutical quitting aids actually are less effective in the 'real world', and if so, why.Read moreRead less
D-Health: A Randomised Trial Of Vitamin D For Prevention Of Cancer And Mortality
Funder
National Health and Medical Research Council
Funding Amount
$2,930,705.00
Summary
There is good evidence that vitamin D is important for maintaining healthy bones. There is now a body of work suggesting that it may play a role in other diseases such as cancer, but there is not yet sufficient information to warrant screening the population to determine their vitamin D levels or recommending routine supplementation. We plan to conduct a large-scale randomised placebo-controlled trial in which we will assess the effect of vitamin D supplementation on mortality, cancer incidence ....There is good evidence that vitamin D is important for maintaining healthy bones. There is now a body of work suggesting that it may play a role in other diseases such as cancer, but there is not yet sufficient information to warrant screening the population to determine their vitamin D levels or recommending routine supplementation. We plan to conduct a large-scale randomised placebo-controlled trial in which we will assess the effect of vitamin D supplementation on mortality, cancer incidence and many other common diseases such as diabetes.Read moreRead less
Understanding Influenza Mortality And The Effects Of Vaccination In The Elderly
Funder
National Health and Medical Research Council
Funding Amount
$446,877.00
Summary
We will analyse mortality from influenza and other causes to estimate the numbers of deaths from other causes that are triggered by influenza in elderly persons, and to test the value of vaccination in preventing those deaths. Our results will help to decide whether an expensive clinical trial is really needed to show the benefit of influenza vaccination on all-cause mortality in the elderly.